Randomized trial · people

Exenatide plus dapagliflozin: UACR fell 39.6% vs 11.0% on placebo

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, exenatide alone did not clearly change kidney markers over 16 weeks. Pairing it with dapagliflozin showed a larger drop in urine albumin from baseline, but that drop was not statistically significant against placebo.

Kind
Randomized trial
Studied in
People
Number studied
66
Published
2021
Journal
Diabetes Obes Metab

What they tested

The team tested whether exenatide twice daily, the diabetes drug dapagliflozin, or both together change markers of kidney function in obese people with type 2 diabetes.

How the study was done

This was a planned secondary analysis of a 16-week randomized, double-blind, placebo-controlled trial in 66 obese people with type 2 diabetes. Groups got exenatide, dapagliflozin, both, or placebo (a dummy treatment).

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking exenatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 16, UACR (the albumin-to-creatinine ratio in 24-hour urine) changed from baseline by -39.6% with the combination (P = 0.001), -18.1% with dapagliflozin, -15.6% with exenatide alone and -11.0% with placebo, and only the combination's change was statistically significant. Against placebo, the combination's UACR difference was -32.2% (P = 0.159), which was not statistically significant. The combination brought an early dip in estimated GFR, a measure of kidney filtering, of -10.4 mL/min/1.73 m2 by cystatin C (P < 0.001) and -4.0 mL/min/1.73 m2 by creatinine (P = 0.129), compared with placebo. Kidney injury molecule-1 relative to creatinine was 43.8% lower with the combination than with placebo (P = 0.129).

What it doesn’t show

This was a small, 16-week secondary analysis that tracked lab markers, not kidney disease outcomes. The combination's edge over placebo on UACR was not statistically significant, so the authors' view that the two drugs work together is tentative.

The paper

van Ruiten et al. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial. Diabetes Obes Metab. 2021.

The compound

More studies on Exenatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking exenatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo